First Comprehensive Analysis Reveals Long-term Effectiveness Of SERMs For Preventing
 

Selective oestrogen receptor modulators (SERMs: tamoxifen, raloxifene, arzoxifene, and lasofoxifene) significantly reduce the risk of developing the most common type of breast cancer among women at both high and average risk of the disease* both during treatment, and for at least 5 years after stopping, according to the first comprehensive analysis of all SERM prevention trials...

More...